ReviewMedicine2025
A case report and literature review on new-onset systemic lupus erythematosus leading to thrombocytopenia in a hemodialysis patient.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSystemic lupus erythematosus (SLE) is a complex autoimmune disease that affects various organs. Disease activity in SLE may diminish following the initiation of dialysis in patients with end-stage renal disease. PATIENT CONCERN: We report the case of a 69-year-old female patient with a prior diagnosis of IgA nephropathy who developed SLE characterized by severe thrombocytopenia after hemodialysis. DIAGNOSES: The patient presented with fever, rash, polyarthralgia, thrombocytopenia, hemolytic anemia, positive antinuclear antibodies, anti-nucleosome antibodies, anticardiolipin antibodies, anti-β2-glycoprotein I antibodies, and decreased complement C3 and C4 levels. She was diagnosed with SLE complicated by hematological damage and immune thrombocytopenia.
interventionsThe treatment included an intravenous infusion of 5% human immunoglobulin at 20 g/day for 5 days combined with an intravenous infusion of methylprednisolone at 500 mg/day for 3 days. Plasma exchange therapy was conducted a total of 3 times. OUTCOMES: The patient was discharged with methylprednisolone and hydroxychloroquine treatment. The platelet count was stable, antinuclear antibody, anti-nucleosome antibody, antiphospholipid antibody, Coombs test, and complement C3 and C4 levels were normal after discharge. LESSONS: In patients with unexplained thrombocytopenia, the possibility of SLE should be considered even after hemodialysis initiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.